Clovis OncologyRecent Data Breaches and Security Report

https://clovisoncology.com  ᛫ 
Last updated October 26, 2018

Company Details

Company Overview

Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

Valuation

Employees

CEO

Location

Recent Data Breaches

Stay informed about the most recent data breaches affecting companies like Clovis Oncology

subscribe to data breach notifications

Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's CSTAR Score ranges from 0 to 950. The higher the score, the more effective a company is in implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Clovis Oncology

Get full security report ›

See UpGuard In Action

Book a call with one of our specialists and we'll arrange a time for a demo.